Abstract:
The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.
Abstract:
A system, method and node for overload control in a network. The method includes the steps of receiving an incoming offer by a node, filtering the offer by an in-throttle to determine if the offer is permitted to be processed by the node prior to processing by the node, processing a permitted offer, and sending the processed offer to a designated target. After processing the permitted offer by the node, the offer may be further filtered prior to sending the offer to the designated target.
Abstract:
A system, method and node for overload control in a network. The method includes the steps of receiving an incoming offer by a node, filtering the offer by an in-throttle to determine if the offer is permitted to be processed by the node prior to processing by the node, processing a permitted offer, and sending the processed offer to a designated target. After processing the permitted offer by the node, the offer may be further filtered prior to sending the offer to the designated target.
Abstract:
The compounds of the Formula (I) ##STR1## wherein R.sub.1 is a C.sub.18-24 alkenyl containing at least two double bonds, or --(CH2)n --CH(NH2)m --COOHX is 0, NH or C.sub.1-4 alkyl-N,Y is CONH.sub.2, COOH or COOMe, wherein Me is hydrogen metal, andR.sub.2 is a side chain of a any amino acid except L-GLU or L-ASP at .alpha.-position or a group of Formula--(CH.sub.2).sub.k --C.sub.6 H.sub.3 --(A).sub.2 (II),--(CH.sub.2).sub.n --X--(CH.sub.2).sub.m --X--M (III) whereink is zero or an integer of 1,n is zero or an integer of 1 to 3,m is zero or an integer of 1 to 4,A is hydroxyl or one A is hydroxyl and the other A is hydrogen.M is H or R.sub.1 --CO andX and R.sub.1 are as defined aboveand their salts having tyrosine kinase inhibitor activity can be used as antitumor agents.
Abstract:
A technique for predicting network load in a communication network is described. For multiple subscriptions, a network load snapshot is provided. The network load snapshot comprises multiple network load records. Each network load record reflects network load caused by an associated subscription in the network at a particular point of time. Each network load record comprises at least one network load value reflecting a network load caused by the corresponding subscription and at least one network load influencing factor reflecting a parameter associated with the subscription which has the potential of influencing the network load value. The network load snapshot is transformed into a predicted network load snapshot comprising at least one predicted network load record, each predicted network load record reflecting estimated network load caused by the corresponding subscription at a particular point of time in the future. The transformation of a network load snapshot into a corresponding predicted network load snapshot is done based on both the network load values and the associated network load influencing factors.
Abstract:
The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.
Abstract:
A method of reducing buffer overflow in a cellular radio network caused by a transfer of data from a buffer in a first cell to a buffer in a second cell when a handover of mobile equipment from said first cell to said second cell occurs. The method comprises temporarily increasing an amount of temporary buffer space required to handle data transferred from the buffer of the first cell to the buffer of the second cell. In one embodiment of the method, prior to increasing the amount of temporary buffer space, the amount of temporary buffer space required is calculated.
Abstract:
A throttle device is coupled with a central processing unit in a node for reducing traffic overload in a Next Generation Network (NGN). The device is coupled with a basic throttle with different levels of traffic priority and both are situated between a source node and a target node for processing traffic. When a traffic offer is received by the throttle, the throttle device by provisionally updating the basic throttle priority levels, determines whether to send the traffic offer on to the source node. If the provisional, traffic priority level is greater than a new traffic priority level the traffic is admitted and rejected if the updated priority level is less than the new traffic priority level.
Abstract:
An apparatus for the production of ozone for an internal combustion engine comprising a non-conductive shell having a first and second opening which allows air to flow therethrough and first and second electrodes disposed inside the shell. The first electrode is spaced a distance from the second electrode, the first electrode having a smaller diameter than, and being aligned axially within the second electrode. The first electrode permits air to flow therethrough. A high voltage source is connected to the first and second electrode, the high voltage source capable of producing a voltage differential on the first and second electrodes sufficient to cause the production of ozone. A change from oxygen to ozone occurs in the air flowing through the apparatus. The shell is preferably cylindrical.
Abstract:
This invention is for a simple device for converting the oxygen in air to ozone which then passes into the combustion chamber of a diesel fueled engine. When this device is used the amount of energy obtained from the diesel is greatly increased.